Jing Zhao

Jing Zhao

Auto-generated profile, based on publicly available information

Jing Zhao

Zhejiang Provincial Research Center for Upper Gastrointestinal Tract Cancer Zhejiang Cancer Hospital Hangzhou 310022 China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2005 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
JCJunxia Chen
Junxia Chen
YGYing Gao
Ying Gao
JLJiwei Liu
Jiwei Liu
YTYu-Xiang Tian
Yu-Xiang Tian
JZJing Zhao
Jing Zhao
XCXiu-Yun Cui
Xiu-Yun Cui

19 May 2022 in Pharmaceutical Biology
Verified
Journal Article
Open access
JZJing Zhao
Jing Zhao
KDKaixin Ding
Kaixin Ding
MHManting Hou
Manting Hou
YLYuanhua Li
Yuanhua Li
XHXiaorong Hou
Xiaorong Hou
ZBZhaofang Bai
Zhaofang Bai
Schisandra chinensis (Turcz.) Baill. (Magnoliaceae) essential oil (SCEO) composition is rich in lignans that are believed to perform protective effects in the liver.This study investigates the effe...

19 September 2025 in Advanced Science
Verified
Journal Article
Open access
JZJing Zhao
Jing Zhao
YMYu‐Bo Ma
Yu‐Bo Ma
RXRui‐Hong Xia
Rui‐Hong Xia
ZJZheng‐Chen Jiang
Zheng‐Chen Jiang
YZYing Zhou
Ying Zhou
LYLi Yuan
Li Yuan
Gastric cancer (GC) is one of the most lethal human malignancies worldwide. Serine metabolism is essential for meeting biosynthetic demands and regulating the redox state of GC cells. This study demonstrates that Skullcapflavone II (SkII) selectively inhibits the proliferation and metastasis of GC cells. Transcriptomic and metabolomic analyses reveal that SkII treatment significantly affects serine metabolism in GC cells, and isotope tracing experiments confirmed that SkII reduces intracellular L‐serine levels by inhibiting uptake rather than de novo synthesis. Furthermore, IHC analysis reveal significant upregulation of the L‐serine transporter SLC1A4 in GC tissues. Binding studies using PELSA, SPR, DARTS, CETSA, and MD suggest that SLC1A4 is a potential direct target of SkII. SkII‐induced disruption of serine metabolism resulted in an imbalance in GSSG/GSH, leading to increased accumulation of intracellular ROS and oxidative stress. This metabolic disruption causes mitochondrial damage, impaired energy production, and increased apoptosis in GC cells. Additionally, in vivo studies reveal that a serine and glycine deficient diet significantly enhanced the antitumor efficacy of SkII, highlighting its potential as a combinatorial therapeutic strategy. These findings provide compelling evidence that SkII is a novel candidate for targeting serine metabolism, suggesting a promising therapeutic approach for treating GC.